Nearly 70% say reducing manual processes is a key priority for working with sites BARCELONA, Spain, Aug. 12, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the 2025 Veeva MedTech Clinical Benchmark, showing that medtech clinical teams are focused on...
Related Questions
How might this news affect investor sentiment given the current sentiment score of 30?
Are there any regulatory or compliance considerations that could affect the implementation of these priorities?
What potential risks or challenges could Veeva face in executing its site collaboration and data‑quality initiatives?
How does the 70% figure for reducing manual processes compare to previous years' benchmarks?
What guidance or outlook did Veeva provide regarding future earnings guidance related to these priorities?
How will Veeva's focus on reducing manual processes affect its revenue growth and profitability?
What is the expected impact of these findings on VEEV's stock price in the short and medium term?
How does Veeva's MedTech Clinical Benchmark compare to similar offerings from competitors like Medtronic, Siemens Healthineers, and Philips?
Will the emphasis on site collaboration and data quality drive higher adoption of Veeva's platform among medtech companies?
What are the implications for Veeva's subscription and services revenue streams?